4.7 Review

Freezing of gait: moving forward on a mysterious clinical phenomenon

Journal

LANCET NEUROLOGY
Volume 10, Issue 8, Pages 734-744

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S1474-4422(11)70143-0

Keywords

-

Funding

  1. Teva Pharmaceutical
  2. Ipsen
  3. Xenoport
  4. Impax Laboratories
  5. Neurogen
  6. Synosia
  7. Neuroderm
  8. Merck
  9. Lilly/Medtronics
  10. Elan
  11. Addex
  12. Lurnbeck
  13. Merz Pharmaceuticals
  14. SynAgile
  15. National Institutes of Health (NIH)
  16. Veterans Administration
  17. National Parkinson Foundation
  18. Michael J Fox Foundation
  19. RJG Foundation
  20. Boehringer Ingelheim
  21. Teva
  22. GlaxoSmithKline
  23. Novartis
  24. European Federation of Neurological Societies
  25. Tijdschrift voor Neurolgie en Neurochiugie
  26. Netherlands Organisation for Scientific Research
  27. Prinses Beatrix Fonds
  28. Stichting Internationaal Parkinson Fonds
  29. van Alkemade-Keuls Foundation
  30. UCB
  31. Schwarz Pharma
  32. Lundbeck
  33. Eisai
  34. Intec Pharma
  35. Solvay
  36. Merz
  37. Biogen
  38. Israel Science Foundation
  39. Hong Kong Polytechnical University
  40. APDM Inc OHSU Hospital
  41. Movement Disorder Society, National Institutes of Health (NIH) [1R13NS67914-1]
  42. Movement Disorder Society

Ask authors/readers for more resources

Freezing of gait (FoG) is a unique and disabling clinical phenomenon characterised by brief episodes of inability to step or by extremely short steps that typically occur on initiating gait or on turning while walking. Patients with FoG, which is a feature of parldnsonian syndromes, show variability in gait metrics between FoG episodes and a substantial reduction in step length with frequent trembling of the legs during FoG episodes. Physiological, functional imaging, and clinical pathological studies point to disturbances in frontal cortical regions, the basal ganglia, and the midbrain locomotor region as the probable origins of FoG. Medications, deep brain stimulation, and rehabilitation techniques can alleviate symptoms of FoG in some patients, but these treatments lack efficacy in patients with advanced FoG. A better understanding of the phenomenon is needed to aid the development of effective therapeutic strategies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available